Letrozole

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 2, 2010, Pages 251-259

  Dellapasqua, Silvia ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Aromatase; Aromatase inhibitors; Breast cancer; Endocrine therapy; Letrozole

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; BEVACIZUMAB; CORTICOSTEROID; EVEROLIMUS; EXEMESTANE; FADROZOLE; FORMESTANE; IMATINIB; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; ENDOMETRIAL DISEASE; FRACTURE; GENE EXPRESSION PROFILING; HEART FAILURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; METASTASIS; MYALGIA; NIGHT SWEAT; NONHUMAN; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PREOPERATIVE TREATMENT; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT RESPONSE; VAGINA BLEEDING;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NITRILES; POSTMENOPAUSE; TRIAZOLES;

EID: 76749118434     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903540246     Document Type: Review

References (62)

1. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009. [Epub ahead of print]
2. Brueggemeier RW. Aromatase inhibitors: new endocrine treatment of breast cancer. Semin Reprod Med 2004;22:31-43
3. Santen RJ, Brodie H, Simpson ER, et al. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009;30(4):343-375
4. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008;44(1):30-38
5. Santen RJ, Samojlik E, Lipton A, et al. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 1977;39(Suppl 6):2948-2958
6. Santen RJ, Santner S, Davis B, et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978;47:1257-1265
7. Santen RJ, Demers LM, Lynch J, et al. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab 1991;73:99-106
8. Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 1996;7:465-469
9. Thuerlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996;7:471-479
10. Dowsett M, Coombes RC. Second generation aromatase inhibitor-4- hydroxyandrostenedione. Breast Cancer Res Treat 1994;30:81-87
11. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004;9:126-136
12. Reddy P. A review of the newer aromatase inhibitors in the management of metastatic breast cancer. J Clin Pharm Ther 1998;23(2):81-90
13. Buzdar AU. New generation aromatase inhibitors-from the advanced to the adjuvant setting. Breast Cancer Res Treat 2002;75(Suppl 1):S13-7; discussion S33-5
14. Bhatnagar AS. The early days of letrozole. Breast Cancer Res Treat 2007;105:3-5
15. Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993;77:324-331
16. Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993;53:266-270 (Pubitemid 23031835)
17. Trunet PF, Mueller P, Bhatnagar AS, et al. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20267, in healthy male subjects. J Clin Endocrinol Metab 1993;77:319-323
18. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461
19. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-3366
20. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606, Erratum in: J Clin Oncol 2001;19:3302
21. Femara package insert. East Hanover, NJ; Novartis Pharmaceuti-cals Corp., 2005
22. Smith IE, Norton A. Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Breast Cancer Res Treat 1998;49(Suppl 1):S67-71, discussion S73-7
23. Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 2007;105:7-17
24. Bhatnagar AS, Brodie AMH, Long BJ, et al. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;76:199-202
25. Bhatnagar AS, Hausler A, Schieweck K, et al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1990;37:1021-1027
26. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 1999;6:187-195
27. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-757
28. Haynes BP, Dowsett M, Miller WR, et al. The pharmacology of letrozole. J Steroid Biochem Mol Biol 2003;87:35-45
29. Lipton A, Demers LM, Harvey HA, et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995;75:2132-2138
30. Bisagni G, Cocconi G, Scaglione F, et al. Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996;7:99-102
31. Ingle JN, Johnson PA, Suman VJ, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997;80:218-224
32. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998;9:639-645
33. Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol 2003;26:S9-16
34. Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 2007;105:19-29
35. Clarke MJ. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 2008;4:CD000487
36. Clarke MJ. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2008;4:CD000486
37. Clarke MJ. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 2008;4:CD000485
38. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-1329
39. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757
40. Coates AS, Keshaviah A, Thuerlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of Study BIG 1-98. J Clin Oncol 2007;25:486-492
41. Mauriac L, Keshaviah A, Debled M, et al.; on behalf of BIG 1-98 Collaborative Group and International Breast Cancer Study Group, Berne, Switzerland. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007;18:859-867
42. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al.; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-776
43. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802
44. Goss PE, Muss HB, Ingle JN, et al. Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 2008;8:411-417
45. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532
46. Paepke S, Tulusan A, Kiesel L, et al. A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc Am Soc Clin Oncol 2003;22:321a
47. Llombart-Cussac A, Galan A, Fuster C, et al. Phase II trial with letrozole (2.8 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR+ operable breast cancer. The Breast 2007;16:S49-50
48. Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996;7:671-675
49. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16:707-715
50. O'Shaughnessy J. A decade of letrozole: FACE. Breast Cancer Res Treat 2007;105:67-74
51. Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol 2006;33:650-656
52. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-49
53. Chu Q, Goldstein L, Murray N, et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients [abstract 3001]. J Clin Oncol 2005;23:192s
54. National Cancer Institute Study comparing GW572016 and letrozole versus letrozole in subjects with advanced or metastatic breast cancer. Available from: http://www.clinicaltrials.gov/show/ NCT00073528. [Cited 25 Aug 2006]
55. Awada A, Cardoso F, Fontaine C, et al. A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femara1), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole [abstract 6043]. Breast Cancer Res Treat 2004;88:S234
56. National Cancer Institute Everolimus and letrozole as preoperative therapy of primary breast cancer in post-menopausal women. Available from: http://www.clinicaltrials. gov/ct/show/NCT00107016. [Cited 25 Aug 2006]
57. Baselga J, Roche H, Fumoleau P, et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study [abstract 1068]. Breast Cancer Res Treat 2005;94:S62
58. National Cancer Institute Study evaluating CCI-779 and letrozole in post-menopausal women with breast cancer. Availble from: http://www. clinicaltrials.gov/show/ NCT00083993. [Cited 25 Aug 2006]
59. Johnston SRD, Semiglazov V, Manikhas G, et al.; On behalf of the R115777 INT-22 Investigators. A randomised, blinded, phase II study of tipifarnib (Zarnestra1) combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy [abstract 5087]. Breast Cancer Res Treat 2005;94:S237
60. National Cancer Institute Study of letrozole plus ZARNESTRA or placebo in the treatment of advanced breast cancer. Available from: http://www. clinicaltrials. gov/show/NCT00050141. [Cited 25 Aug 2006]
61. Traina TA, Rugo H, Caravelli J, et al. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) [abstract 3050]. J Clin Oncol 2006;24:133s
62. Aun B, Dice K, ALbarracin C, et al. The combination of letrozole and imatinib mesylate for metastatic breast cancer [abstract 6046]. Breast Cancer Res Treat 2004;88:S235